Cargando…
AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIF...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061420/ https://www.ncbi.nlm.nih.gov/pubmed/33898423 http://dx.doi.org/10.3389/fcell.2021.635476 |
_version_ | 1783681562771980288 |
---|---|
author | Lin, Bo Dong, Xu Wang, Qiujiao Li, Wei Zhu, Mingyue Li, Mengsen |
author_facet | Lin, Bo Dong, Xu Wang, Qiujiao Li, Wei Zhu, Mingyue Li, Mengsen |
author_sort | Lin, Bo |
collection | PubMed |
description | Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIFs) to inhibit the binding of AFP to intracellular proteins or its receptors is the basis of a new strategy for the treatment of HCC and other cancers. In addition, AIFs can be combined with drugs and delivery agents to target treatments to cancer. AIFs conjugated to anticancer drugs not only destroy cancer cells with these drugs but also activate immune cells to kill cancer cells. Furthermore, AIF delivery of drugs relieves immunosuppression and enhances chemotherapy effects. The synergism of immunotherapy and targeted chemotherapy is expected to play an important role in enhancing the treatment effect of patients with cancer. AIF delivery of drugs will be an available strategy for the targeted treatment of cancer in the future. |
format | Online Article Text |
id | pubmed-8061420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80614202021-04-23 AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers Lin, Bo Dong, Xu Wang, Qiujiao Li, Wei Zhu, Mingyue Li, Mengsen Front Cell Dev Biol Cell and Developmental Biology Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIFs) to inhibit the binding of AFP to intracellular proteins or its receptors is the basis of a new strategy for the treatment of HCC and other cancers. In addition, AIFs can be combined with drugs and delivery agents to target treatments to cancer. AIFs conjugated to anticancer drugs not only destroy cancer cells with these drugs but also activate immune cells to kill cancer cells. Furthermore, AIF delivery of drugs relieves immunosuppression and enhances chemotherapy effects. The synergism of immunotherapy and targeted chemotherapy is expected to play an important role in enhancing the treatment effect of patients with cancer. AIF delivery of drugs will be an available strategy for the targeted treatment of cancer in the future. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8061420/ /pubmed/33898423 http://dx.doi.org/10.3389/fcell.2021.635476 Text en Copyright © 2021 Lin, Dong, Wang, Li, Zhu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author (s) and the copyright owner (s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Lin, Bo Dong, Xu Wang, Qiujiao Li, Wei Zhu, Mingyue Li, Mengsen AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers |
title | AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers |
title_full | AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers |
title_fullStr | AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers |
title_full_unstemmed | AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers |
title_short | AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers |
title_sort | afp-inhibiting fragments for drug delivery: the promise and challenges of targeting therapeutics to cancers |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061420/ https://www.ncbi.nlm.nih.gov/pubmed/33898423 http://dx.doi.org/10.3389/fcell.2021.635476 |
work_keys_str_mv | AT linbo afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers AT dongxu afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers AT wangqiujiao afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers AT liwei afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers AT zhumingyue afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers AT limengsen afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers |